DDInter258 DDInter1094
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may lead to a major life threatening interaction when taken with {v} Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Dezocine
Dezocine {u} (Compound) resembles {v} (Compound) Estradiol
Estradiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Pentazocine
Pentazocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Dezocine
Dezocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Levorphanol
Levorphanol {u} (Compound) resembles {v} (Compound) Estrone
Estrone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Pentazocine
Pentazocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Dezocine
Dezocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may lead to a major life threatening interaction when taken with {v} Sufentanil
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may lead to a major life threatening interaction when taken with Lorlatinib
Butorphanol (Compound) resembles Dezocine (Compound) and Dezocine (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Butorphanol (Compound) resembles Pentazocine (Compound) and Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Butorphanol (Compound) resembles Dezocine (Compound) and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Butorphanol (Compound) resembles Nalbuphine (Compound) and Nalbuphine (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Lorlatinib
Butorphanol (Compound) resembles Levorphanol (Compound) and Levorphanol (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Butorphanol (Compound) resembles Pentazocine (Compound) and Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Butorphanol (Compound) resembles Dezocine (Compound) and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may lead to a major life threatening interaction when taken with Sufentanil and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib